

Supplemental Table S1. Quality assessment of included clinical studies.

Source	Selection				Comparability ⁵	Exposure			Total ⁹
Author, Year	Definition ¹	Representative ²	Selection ³	Definition ⁴		Ascertainment ⁶	Method ⁷	Technique ⁸	
Aboushousha, 2019 [36]	★	★	★	0	0	★	0	★	5
Akkus, 2020 [37]	★	★	★	0	★	★	★	★	7
Foster, 2014 [38]	★	0	0	0	0	★	0	★	3
Hemani, 2005 [39]	★	★	★	★	0	★	★	★	7
Ishiguro, 2005 [40]	★	★	★	★	★	★	★	★	8
Konopka, 2020 [24]	★	★	0	0	★	★	★	★	6
Kuniyasu, 2003 [41]	★	★	0	0	★	★	0	★	5
Ravenna, 2009 [42]	★	★	★	0	0	★	0	★	5
Zhao, 2014 [43]	★	★	★	0	0	★	★	★	6

¹Indicates that cases are independently validated for prostate cancer (PCa) by a trained histopathologist (0, 1 star); ²cases are from a representative population or drawn from the same community (0, 1); ³control of non-PCa prostate tissue (prostatitis, benign prostate hyperplasia, or healthy prostate) was included (0, 1); ⁴control of normal prostate was included (0, 1); ⁵specified as non-metastatic vs. metastatic or androgen-sensitive vs. androgen-insensitive PCa (0, 1, 2); ⁶PCa samples were attained from medical records (0, 1); ⁷collection method of PCa tissue was included (0, 1); ⁸approved identification technique was used to measure RAGE expression (0, 1); ⁹total: minimum equals 1 star; maximum equals 9 stars.